Exhibit 5.1
7800 Rancharrah Parkway PH (775) 788-2200 | FX (775) 786-1177 fennemorecraig.com
|
October 26, 2020
Kintara Therapeutics, Inc.
12707 High Bluff Dr., Suite 200
San Diego, CA 92130
Re: Registration of Common Stock of Kintara Therapeutics, Inc.
Ladies and Gentlemen:
We are acting as special Nevada counsel for Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), in connection with the registration under a Registration Statement on Form S-3 (the “Registration Statement”) by the Company under the Securities Act of 1933, as amended (the “Act”) of 34,990,252 shares (the “Registered Stock”) of the Company’s common stock, par value $.001 per share (the “Common Stock”) issuable pursuant to the terms of the Preferred Stock, as defined below.
We have examined originals or copies of each of the documents listed below:
1.The Articles of Incorporation of the Company, as amended, as certified by an officer of the Company as of the date hereof;
2.The Bylaws of the Company, as certified by an officer of the Company as of the date hereof;
3.Resolutions of the Board of Directors of the Company relating to the registration and issuance of the Registered Stock, as certified by an officer of the Company as of the date hereof;
4.(i) The Certificate of Designation of Preferences, Rights and Limitations (the “C-1 COD”) of Series C-1 Preferred Stock of the Company (the “Series C-1 Stock”), (ii) the Certificate of Designation of Preferences, Rights and Limitations (the “C-2 COD”) of Series C-2 Preferred Stock of the Company (the “Series C-2 Stock”) and (iii) the Certificate of Designation of Preferences, Rights and Limitations (the “C-3 COD, and collectively, with the C-1 COD and the C-2 COD, the “COD”) of Series C-3 Preferred Stock of the Company (the “Series C-3 Stock”, and collectively with the Series C-1 Stock and the Series C-2 Stock, the “Preferred Stock), in each case as filed with the Secretary of State of the State of Nevada; and
5.The Registration Statement.
We have examined originals or copies of such other corporate records, certificates of corporate officers and public officials and other agreements and documents as we have deemed necessary or advisable for purposes of this opinion letter. We have relied upon the certificates of all public officials and corporate officers with respect to the accuracy of all factual matters contained therein.
Without limiting the generality of the foregoing, in our examination, we have, with your permission, assumed without independent verification, that (i) all documents submitted to us as originals are authentic, the signatures on all documents that we examined are genuine, and all documents submitted to us as certified, conformed, photostatic, electronic or facsimile copies conform to the original document; and (ii) all corporate records made available to us by the Company and all public records we have reviewed are accurate and complete. We note that the Company has reserved, and assume it will continue to maintain reserved, a sufficient number of shares of its duly authorized, but unissued, Common Stock as is necessary to provide for the issuance of the Registered Stock.
Based upon the foregoing, and subject to the following, it is our opinion that the issuance of the Registered Stock was duly authorized by the Company and when issued and paid for in accordance with the terms of the applicable COD, the Registered Stock will be validly issued, fully paid and nonassessable.
We express no opinion as to the laws of any jurisdiction other than the laws of the State of Nevada. The opinions expressed above concern only the effect of the laws (excluding the principles of conflict of laws) of the State of Nevada currently in effect. We assume no obligation to supplement this opinion if any applicable laws change after
Kintara Therapeutics, Inc.
October 26, 2020
Page 2
the date of this opinion, or if we become aware of any facts that might change the opinions expressed above after the date of this opinion.
This opinion is issued in the State of Nevada. By issuing this opinion, Fennemore Craig, P.C. (i) shall not be deemed to be transacting business in any other state or jurisdiction other than the State of Nevada and (ii) does not consent to the jurisdiction of any state other than the State of Nevada. Any claim or cause of action arising out of the opinions expressed herein must be brought in the State of Nevada. Your acceptance of this opinion shall constitute your agreement to the foregoing.
We consent to your filing of this opinion as an exhibit to the Registration Statement and further consent to the use of our name wherever appearing in the Registration Statement. We further consent to the incorporation by reference of this opinion and consent in any registration statement filed pursuant to Rule 462(b) under the Act with respect to the Common Stock. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Act, the rules and regulations of the Securities and Exchange Commission promulgated thereunder, or Item 509 of Regulation S-K. The opinions expressed in this letter are rendered as of the date hereof, and we express no opinion as to circumstances or events that may occur subsequent to such date. Our opinion is expressly limited to the matters set forth above and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company or the Common Stock.
Very truly yours,
/s/ Fennemore Craig, P.C.
Fennemore Craig, P.C.
CDOL